Jan M. Lundberg

Dr. Jan Lundberg has over two decades of executive leadership experience in the pharmaceutical sector and held c-suite positions with leading companies, including Eli Lilly and AstraZeneca. Dr. Lundberg most recently held the position of executive vice president, science and technology, and president, Lilly Research Laboratories at Eli Lilly. During his career he has led the development of more than 200 candidate drugs, with 25 approved products across multiple therapeutic areas. Before joining AstraZeneca, Dr. Lundberg held the position of Professor of Pharmacology at the Karolinska Institute in Solna, Sweden. In addition to his significant industry experience, Dr. Lundberg is the co-founder of Aerocrine AB and currently serves on the boards of directors of Anocca, Ardelyx, Betagenon, Image Analysis Group, Metabolon and TB Alliance.

Dr. Lundberg completed 4 years of medical school at the University of Gothenburg and his doctorate at the Karolinska Institute.